Non-invasive Brain Stimulation to Improve Unsteady Gait in Older Adults (StimGait)

Fall Clinical Trial

Official title:

Modulating Brain Networks to Reduce Gait Variability in Older Adults at Risk of Falling

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06008431
• Other study ID #: Pro00057363
• Secondary ID: K01AG075252
• Status: Not yet recruiting
• Phase: N/A
• Start date: November 1, 2023
• Est. completion date: December 31, 2024

Study information

• Verified date: September 2023
• Source: Hebrew SeniorLife
• Contact: On-Yee Lo, Ph.D.
• Phone: 617-931-5331
• Email: AmyLo[@]hsl.harvard.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Walking is a complex and continuous task that entails repetitive motions of the body. Relatively high gait variability sensitively predicts falls and cognitive decline in older adults. Previous work has identified an unique brain network relationship linked to gait variability and its relevant cognitive function (i.e., sustained attention). This project aims to develop a non-invasive brain stimulation montage designed to modulate the shared brain networks dynamics and to demonstrate its effects on resting state functional connectivity, gait and cognitive performance in older adults at risk for falls.

Description:

This is a randomized controlled trial to examine the efficacy of a non-invasive brain stimulation intervention of tDCS to improve unsteady gait in older adults. The investigators will enroll 30 older adults with elevated gait variability. Participants will be randomized into one of two arms: a) 10 sessions of tDCS and b) 5 sessions of sham stimulation followed by 5 sessions of tDCS. Participants will engage in a set of pre-intervention assessments, the brain stimulation intervention - consisting of 10, once-daily, 20-min stimulation sessions over a 2-week period, and a set of post-intervention assessments. This project is expected to demonstrate that tDCS can be used to reduce gait variability in older adults.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Aged 65 and above.
• Ability to speak and read English.
• Ability to walk independently and continuously for at least 1 minute.
• Elevated gait variability as defined by a coefficient of variation (CoV) about average stride time larger and equal to 0.025 during straight-line walking at preferred speed.

Exclusion Criteria:

• More than mild cognitive impairment defined by a Montreal Cognitive Assessment (MoCA) score less than 18.
• Parkinson's disease, multiple sclerosis, stroke, active brain tumor, or other neurological disorders.
• Self-reported pain or lower extremity deformity that significantly disrupts walking.
• Contraindications to MRI or tDCS.
• An episode of acute illness or exacerbation of a diagnosis that requires hospitalization or active treatment within the past 3 months.
• Current treatment for congestive heart failure, angina, uncontrolled arrythmia, deep vein thrombosis, or other uncontrolled cardiovascular events.
• Myocardial infarction, coronary artery bypass grafting, angioplasty, or other cardiac conditions within the past 3 months,
• Active cancer for which chemo/radiation therapy is being received.
• Psychiatric co-morbidity including major depressive disorder, schizophrenia, psychosis, or other psychiatric illness.
• Recent use of any sedating medications (sedatives, anti-psychotics, hypnotics, anti-depressants) or change in medication within the previous month.
• Chronic vertigo or other diagnosed vestibular disorders.
• Legal blindness, visual impairments that cannot be corrected with glasses, contact lenses, medicine, or surgery.
• Those without WiFi access
• Those who do not plan to live in their current homes for the duration of the study

Related Conditions & MeSH terms

• Fall
• Gait Disorders, Neurologic
• Gait, Unsteady
• Mobility Limitation

Intervention

Device:
• Transcranial direct current stimulation (tDCS) (active)
The tDCS montage is developed to modulate the functional connectivity between the dorsal attention network and the default network.
• Transcranial direct current stimulation (tDCS) (Sham)
The tDCS "Acti-" Sham montage is developed to recreate the cutaneous sensations associated with tDCS, yet essentially a null electrical field over the networks of interest.

Locations

Country	Name	City	State
United States	Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Hebrew SeniorLife	National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Gait variability	This measure is captured by both Mobility Lab (APDM Inc) and the smart phone App. Gait variability is defined as the coefficient of variation to validated stride times.	Baseline, Immediate post-intervention, 1 month follow up
Secondary	Gait speed	This measure is captured by Mobility Lab (APDM InC). Gait speed id defined by the time one takes to walk a specified distance.	Baseline, Immediate post-intervention, 1 month follow up
Secondary	Dual-task gait performance	Participants will be asked to walk under two conditions: 1) walk at a comfortable, self-selected speed and 2) walk while counting backward by 1' or 3's from a random 3-digit number. Dual-task gait characteristics will be captured while the participants concurrently walk and count. We will further calculate the cost one takes to complete the dual-task walking from walking at a comfortable, self-selected speed.	Baseline, Immediate post-intervention, 1 month follow up
Secondary	Accuracy (d prime) on the gradual onset continuous performance task (gradCPT)	The gradCPT is a computer-based cognitive task designed to measure sustained attention. Accuracy (d prime) on the gradCPT can be derived from the gradCPT analysis tool box.	Baseline, Immediate post-intervention, 1 month follow up